Table 1.
Patients’ characteristics
| n | % | ||
|---|---|---|---|
| number of patients | 30 | (100) | |
| gender | male : female | 1 : 1.5 | |
| age (years) | median (range) | 51 years (21 - 78) | |
| localization | frontal | 10 | (34) |
| insular | 5 | (17) | |
| temporal | 4 | (14) | |
| parietal | 3 | (10) | |
| central | 3 | (10) | |
| occipital | 1 | (3) | |
| trigonal | 1 | (3) | |
| brainstem | 1 | (3) | |
| thalamus | 1 | (3) | |
| corpus callosum | 1 | (3) | |
| MRI contrast - enhancement | |||
| significant | ring-like | 11 | (36) |
| nodular | 2 | (7) | |
| non-significant | none | 12 | (40) |
| patchy/faint | 3 | (10) | |
| focal | 2 | (7) | |
| type of surgery | resection | 19 | (64) |
| stereotactic biopsy | 10 | (33) | |
| open biopsy | 1 | (3) | |
| target for iOP tumour sampling | |||
| MR CE | 13 | (43) | |
| PET | 15 | (50) | |
| CSI | 2 | (7) | |
| diagnosis | |||
| HGG | glioblastoma (WHO grade IV) | 12 | (40) |
| gliosarcoma (WHO grade IV) | 1 | (3) | |
| anaplastic astrocytoma (WHO grade III) | 5 | (18) | |
| anaplastic oligodendroglioma (WHO grade III) | 2 | (7) | |
| mixed oligoastocytoma (WHO grade III) | 1 | (3) | |
| LGG | oligodendroglioma (WHO grade II) | 4 | (13) |
| diffuse astrocytoma (WHO grade II) | 4 | (13) | |
| mixed oligoastocytoma (WHO grade II) | 1 | (3) | |
| IDH1 mutational status | |||
| IDH1-R132H negative tumour | 15 | (50) | |
| IDH1-R132H positive tumour | 15 | (50) | |
CE contrast - enhancement; CSI chemical shift imaging; HGG high-grade gliomas; iOP intraoperative, LGG low-grade gliomas, MR magnetic resonance imaging, PET positron emission tomography, WHO World Health Organization; IDH1 isocitrate dehydrogenase 1